APPENDIX 9: RAPID IMPACT ASSESSMENT SCREENING FORM
Name of procedural document
Directorate and Service Area
Name, job title and contact details of person
completing the assessment
Date:
Medicines Management Policy
Trust-wide
Dr Bettina Kluettgens, Pharmacy
Governance Lead, 402441
March 2014
EXECUTIVE SUMMARY
This policy does not have any identified impact for any of the protected characteristics
Impact
Indirect discrimination can
happen if prescribers do not
take account of race, gender,
disability, religion etc.
Patients with
communications difficulties
might be disadvantaged if
appropriate communication
is not used by prescribers
Action
The policy encourages
prescribers to be aware of
not causing indirect
discrimination when
prescribing medicines
The policy encourages
prescribers to ensure their
communication supports
patients with
communications
difficulties
Result
Risk minimised
Risk minimised
(If you need to progress to a full impact assessment, please include this as an action,
above.)
1.
What is the main purpose of this policy / plan / service?
Govern unlicensed medicines
2.
Who does it affect? Please tick as appropriate.
Carers x
3.
Staff x
Patients x
Other (please specify)
What impact is it likely to have on different sections of the community /
workforce, considering the “protected characteristics” below?
Medicines Management Policy
Ratified by: Clinical Effectiveness Committee: 20th March 2014
Review date: September 2016
Page 1 of 3
Please insert a tick in the appropriate box √
Protected
Characteristics
Positive
impact -- it
could benefit
Age
x
Disability
x
Negative
impact -- it
treats them
less
favourably or
could do
Negative impact -they could find it
harder than others to
benefit from it or they
could be
disadvantaged by it
Non-impact –
missed
opportunities
to promote
equality
Neutral -unlikely to
have a
specific effect
Sex
including
Transgender and
Pregnancy / Maternity
x
Race
x
Religion / belief
x
Sexual orientation
including
Marriage / Civil
Partnership
x
In identifying the impact of your policy across these characteristics, please consider the
following issues:
-
Fairness - Does it treat everyone justly?
Respect - Does it respect everyone as a person?
Equality - Does it give everyone an equal chance to get whatever it is offering?
Dignity - Does it treat everyone with dignity?
Autonomy - Does it recognise everyone’s freedom to make decisions for
themselves?
If you have any negative impacts, you will need to progress to a full impact assessment.
Medicines Management Policy
Ratified by: Clinical Effectiveness Committee: 20th March 2014
Review date: September 2016
Page 2 of 3
4. If you have identified any positive impacts (see above), what will you do to
make the most of them?
“Protected characteristic”
Race, Religion, Disability, Gender
affected:
Issue
Risk of discrimination
Who did you ask to
What did you find out
What did you learn or
understand the issues or
about?
confirm?
whose work did you look
at?
Professional bodies
Action
Encourage prescribers to
take into account race,
religion, disability, gender
and communication
difficulties
Good practice guidance
Action as a result of above
By who?
Policy Writer
When?
During drafting in 2010
5. If you have identified any missed opportunities (“non-impacts”), what will you
do to take up any opportunities to promote equality?
“Protected characteristic”
affected:
Issue
Who did you ask to
What did you find out
What did you learn or
understand the issues or
about?
confirm?
whose work did you look
at?
Action
Action as a result of above
By who?
When?
6. If you have a identified a neutral impact, show who you have consulted or
asked to confirm that this is the case, in the table below:
Who did you ask or consult to confirm your neutral impacts?
Medicines Management Group (28/02/14),
Assistant Directors of Nursing (04/04/14),
Divisional Directors (04/04/14),
Governance Managers (04/04/14) PEP (03/04/14)
If you need help with any aspect of this assessment, please contact:
Tony Williams
Equality and Diversity Manager
Ext: 6942
anthony.williams1@nhs.net
Medicines Management Policy
Ratified by: Clinical Effectiveness Committee: 20th March 2014
Review date: September 2016
Page 3 of 3